Basal cell carcinoma is the most common skin tumour, with the majority of the cases occurring on the head and neck district, where cosmetic and functional results are crucial. It can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for most lesions, but aggressive, recurrent, or unresectable tumours can be challenging to manage. Advanced basal cell carcinoma includes high recurrence risk subtypes, in which standard therapies demonstrate lack of efficacy. This led to a need for investigating more deeply the pathogenesis of the disease and to the discovery of the implication of the hedgehog pathway. The development of systemic inhibitors of this pathway provides new treatment options for patients with advanced disease, resulting in survival improvement. Food and Drug Administration, before, and European Medicines Agency later approved 2 Hedgehog pathway inhibitors for the treatment of advanced basal cell carcinomas, vismodegib and sonidegib. Here, we present a review of the current English language literature trying to analyze differences in the 2 drugs as a head-to-head comparison between them has not already been documented in a randomized controlled clinical trial. Although vismodegib and sonidegib showed similar efficacy and safety profiles, in an indirect comparison scenario, sonidegib has shown slightly better outcomes in locally advanced basal cell carcinoma than vismodegib. They present different molecular structures, as they bind different residues on their targets and develop resistance for different mutations. In a future scenario, clinical trials comparing the 2 drugs are needed, as well as expanding data on discontinuation of therapy and/or consequential administration of them, with the aim to improve our clinical practise.

1.
Donovan
J
.
Review of the hair follicle origin hypothesis for basal cell carcinoma
.
Dermatol Surg
.
2009 Sep
;
35
(
9
):
1311
23
.
2.
Dika
E
,
Fanti
PA
,
Ismaili
A
,
Misciali
C
,
Vaccari
S
,
Barisani
A
,
.
Basal cell carcinoma margin delineation: is curettage useful? A surgical and histological study
.
J Dermatolog Treat
.
2013 Jun
;
24
(
3
):
238
42
.
3.
Trakatelli
M
,
Morton
C
,
Nagore
E
,
Ulrich
C
,
Del
Marmol
V
,
Peris
K
,
.
Update of the European guidelines for basal cell carcinoma management
.
Eur J Dermatol
.
2014 Jun
;
24
(
3
):
312
29
.
4.
Dika
E
,
Fanti
PA
,
Venturi
M
,
Baraldi
C
,
Patrizi
A
.
Non-melanoma skin cancer: to Mohs or not to Mohs
.
G Ital Dermatol Venereol
.
2015 Oct
;
150
(
5
):
630
2
.
5.
Dika
E
,
Fanti
PA
,
Christman
H
,
Ravaioli
GM
,
Patrizi
A
.
Videodermoscopy and curettage: the value of simple procedures during Mohs surgery
.
Dermatol Surg
.
2017 Dec
;
43
(
12
):
1411
7
.
6.
Kauvar
AN
,
Cronin
T
,
Roenigk
R
,
Hruza
G
,
Bennett
R
;
American Society for Dermatologic Surgery
.
Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods
.
Dermatol Surg
.
2015 May
;
41
(
5
):
550
71
.
7.
Campione
E
,
Di
Prete
M
,
Del
Principe
I
,
Diluvio
L
,
Citarella
L
,
Orlandi
A
,
.
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports
.
J Med Case Rep
.
2016 Mar
;
10
:
57
.
8.
Diluvio
L
,
Lanna
C
,
Lozzi
F
,
Palumbo
V
,
Bianchi
L
,
Campione
E
.
Basal cell carcinomas treated with 0.5% 5-fluorouracil and 10% salicylic acid topical solution
.
Dermatol Ther
.
2019
;
32
(
3
):
e12908
.
9.
Lear
JT
,
Corner
C
,
Dziewulski
P
,
Fife
K
,
Ross
GL
,
Varma
S
,
.
Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective
.
Br J Cancer
.
2014 Oct
;
111
(
8
):
1476
81
.
10.
Morgan
FC
,
Ruiz
ES
,
Karia
PS
,
Besaw
RJ
,
Neel
VA
,
Schmults
CD
.
Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter
.
J Am Acad Dermatol
.
2019 Oct
.http://dx.doi.org/10.1016/j.jaad.2019.09.075
11.
Cameron
MC
,
Lee
E
,
Hibler
BP
,
Barker
CA
,
Mori
S
,
Cordova
M
,
.
Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations
.
J Am Acad Dermatol
.
2019
;
80
(
2
):
303
17
.
12.
Walling
HW
,
Fosko
SW
,
Geraminejad
PA
,
Whitaker
DC
,
Arpey
CJ
.
Aggressive basal cell carcinoma: presentation, pathogenesis, and management
.
Cancer Metastasis Rev
.
2004 Dec
;
23
(
3–4
):
389
402
.
13.
Saldanha
G
,
Fletcher
A
,
Slater
DN
.
Basal cell carcinoma: a dermatopathological and molecular biological update
.
Br J Dermatol
.
2003 Feb
;
148
(
2
):
195
202
.
14.
AbdullGaffar
B
.
The prevalence and importance of clefts in cutaneous neoplasms
.
Pathology
.
2012 Apr
;
44
(
3
):
267
70
.
15.
Rippey
JJ
,
Rippey
E
.
Characteristics of incompletely excised basal cell carcinomas of the skin
.
Med J Aust
.
1997 Jun
;
166
(
11
):
581
3
.
16.
Stockfleth
E
,
Sterry
W
.
New treatment modalities for basal cell carcinoma
.
Recent Results Cancer Res
.
2002
;
160
:
259
68
.
17.
Bichakjian
CK
,
Olencki
T
,
Aasi
SZ
,
Alam
M
,
Andersen
JS
,
Berg
D
,
.
Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology
.
J Natl Compr Canc Netw
.
2016
;
14
(
5
):
574
97
.
18.
Tebcherani
AJ
,
de Andrade
HF
,
Sotto
MN
.
Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples
.
Mod Pathol
.
2012 Oct
;
25
(
10
):
1345
53
.
19.
Katona
TM
,
Perkins
SM
,
Billings
SD
.
Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma
.
J Cutan Pathol
.
2008 Feb
;
35
(
2
):
174
9
.
20.
Webb
DV
,
Mentrikoski
MJ
,
Verduin
L
,
Brill
LB
,
Wick
MR
.
Basal cell carcinoma vs basaloid squamous cell carcinoma of the skin: an immunohistochemical reappraisal
.
Ann Diagn Pathol
.
2015 Apr
;
19
(
2
):
70
5
.
21.
Jayaraman
SS
,
Rayhan
DJ
,
Hazany
S
,
Kolodney
MS
.
Mutational landscape of basal cell carcinomas by whole-exome sequencing
.
J Invest Dermatol
.
2014 Jan
;
134
(
1
):
213
20
.
22.
Rosso
S
,
Zanetti
R
,
Martinez
C
,
Tormo
MJ
,
Schraub
S
,
Sancho-Garnier
H
,
.
The multicentre south European study ‘Helios’. II: different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin
.
Br J Cancer
.
1996 Jun
;
73
(
11
):
1447
54
.
23.
Le
H
,
Kleinerman
R
,
Lerman
OZ
,
Brown
D
,
Galiano
R
,
Gurtner
GC
,
.
Hedgehog signaling is essential for normal wound healing
.
Wound Repair Regen
.
2008 Nov–Dec
;
16
(
6
):
768
73
.
24.
Bakshi
A
,
Chaudhary
SC
,
Rana
M
,
Elmets
CA
,
Athar
M
.
Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond
.
Mol Carcinog
.
2017 Dec
;
56
(
12
):
2543
57
.
25.
Heo
JS
,
Lee
MY
,
Han
HJ
.
Sonic hedgehog stimulates mouse embryonic stem cell proliferation by cooperation of Ca2+/protein kinase C and epidermal growth factor receptor as well as Gli1 activation
.
Stem Cells
.
2007 Dec
;
25
(
12
):
3069
80
.
26.
Epstein
EH
.
Basal cell carcinomas: attack of the hedgehog
.
Nat Rev Cancer
.
2008 Oct
;
8
(
10
):
743
54
.
27.
Otsuka
A
,
Levesque
MP
,
Dummer
R
,
Kabashima
K
.
Hedgehog signaling in basal cell carcinoma
.
J Dermatol Sci
.
2015 May
;
78
(
2
):
95
100
.
28.
Reifenberger
J
,
Wolter
M
,
Knobbe
CB
,
Köhler
B
,
Schönicke
A
,
Scharwächter
C
,
.
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas
.
Br J Dermatol
.
2005 Jan
;
152
(
1
):
43
51
.
29.
Verkouteren
JAC
,
Ramdas
KHR
,
Wakkee
M
,
Nijsten
T
.
Epidemiology of basal cell carcinoma: scholarly review
.
Br J Dermatol
.
2017 Aug
;
177
(
2
):
359
72
.
30.
Gorlin
RJ
.
Nevoid basal cell carcinoma syndrome (Gorlin syndrome)
.
Orphanet J Rare Dis
.
2004 Dec
;
3
(
6
):
32
9
.
31.
Long
B
,
Zhu
H
,
Zhu
C
,
Liu
T
,
Meng
W
.
Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients
.
J Exp Clin Cancer Res
.
2011 Jan
;
30
:
8
.
32.
Dahlin
AM
,
Hollegaard
MV
,
Wibom
C
,
Andersson
U
,
Hougaard
DM
,
Deltour
I
,
.
CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma
.
J Neurooncol
.
2015 Oct
;
125
(
1
):
75
8
.
33.
Liu
Y
,
Huber
RM
,
Kiefl
R
,
Tufman
A
,
Kauffmann-Guerrero
D
.
Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells
.
Anticancer Res
.
2020 Mar
;
40
(
3
):
1451
8
.
34.
Dummer
R
,
Ascierto
PA
,
Basset-Seguin
N
,
Dréno
B
,
Garbe
C
,
Gutzmer
R
,
.
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion
.
J Eur Acad Dermatol Venereol
.
2020 Jan
.
Epub ahead of print
.http://dx.doi.org/10.1111/jdv.16230
35.
Cooper
MK
,
Porter
JA
,
Young
KE
,
Beachy
PA
.
Teratogen-mediated inhibition of target tissue response to Shh signaling
.
Science
.
1998 Jun
;
280
(
5369
):
1603
7
.
36.
Jimeno
A
,
Weiss
GJ
,
Miller
WH
,
Gettinger
S
,
Eigl
BJ
,
Chang
AL
,
.
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
.
Clin Cancer Res
.
2013 May
;
19
(
10
):
2766
74
.
37.
Epstein
EH
,
Lear
J
,
Saldanha
G
,
Tang
JY
,
Harwood
C
.
Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome
.
J Clin Oncol
.
2018
;
36
(
15 Suppl
):
e21626
.
38.
Robarge
KD
,
Brunton
SA
,
Castanedo
GM
,
Cui
Y
,
Dina
MS
,
Goldsmith
R
,
.
GDC-0449-a potent inhibitor of the hedgehog pathway
.
Bioorg Med Chem Lett
.
2009 Oct
;
19
(
19
):
5576
81
.
39.
Pan
S
,
Wu
X
,
Jiang
J
,
Gao
W
,
Wan
Y
,
Cheng
D
,
.
Discovery of NVP-LDE225, a potent and selective smoothened antagonist
.
ACS Med Chem Lett
.
2010 Jun
;
1
(
3
):
130
4
.
40.
Commissioner O of the FDA approves first treatment for advanced form of the second most common skin cancer [Internet]
.
FDA
.
2020 Mar
[cited 2020 Apr 18]. Available from:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer-0.
41.
Anonymous
.
Odomzo [Internet]
.
Eur Medicines Agency
.
2018 Sep
[cited 2020 Apr 18]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/odomzo.
42.
Anonymous
.
Erivedge [Internet]
.
Eur Medicines Agency
.
2018 Sep
[cited 2020 Apr 19]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge.
43.
Kim
J
,
Tang
JY
,
Gong
R
,
Kim
J
,
Lee
JJ
,
Clemons
KV
,
.
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
.
Cancer Cell
.
2010 Apr
;
17
(
4
):
388
99
.
44.
Kim
DJ
,
Kim
J
,
Spaunhurst
K
,
Montoya
J
,
Khodosh
R
,
Chandra
K
,
.
Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma
.
J Clin Oncol
.
2014 Mar
;
32
(
8
):
745
51
.http://dx.doi.org/10.1200/JCO.2013.49.9525
45.
Sekulic
A
,
Migden
MR
,
Oro
AE
,
Dirix
L
,
Lewis
KD
,
Hainsworth
JD
,
.
Efficacy and safety of vismodegib in advanced basal-cell carcinoma
.
N Engl J Med
.
2012 Jun
;
366
(
23
):
2171
9
.
46.
Sekulic
A
,
Migden
MR
,
Basset-Seguin
N
,
Garbe
C
,
Gesierich
A
,
Lao
CD
,
.
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
.
BMC Cancer
.
2017 May 16
;
17
(
1
):
332
.
47.
Teperino
R
,
Amann
S
,
Bayer
M
,
McGee
SL
,
Loipetzberger
A
,
Connor
T
,
.
Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat
.
Cell
.
2012 Oct
;
151
(
2
):
414
26
.
48.
Dessinioti
C
,
Antoniou
C
,
Stratigos
AJ
.
From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots
.
Br J Dermatol
.
2017
;
177
(
6
):
1485
94
.
49.
Yang
H
,
Cong
WN
,
Yoon
JS
,
Egan
JM
.
Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds
.
Cancer Med
.
2015 Feb
;
4
(
2
):
245
52
.
50.
Basset-Séguin
N
,
Hauschild
A
,
Kunstfeld
R
,
Grob
J
,
Dréno
B
,
Mortier
L
,
.
Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial
.
Eur J Cancer
.
2017
;
86
:
334
48
.
51.
Dréno
B
,
Kunstfeld
R
,
Hauschild
A
,
Fosko
S
,
Zloty
D
,
Labeille
B
,
.
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
.
Lancet Oncol
.
2017
;
18
(
3
):
404
12
.
52.
Migden
MR
,
Guminski
A
,
Gutzmer
R
,
Dirix
L
,
Lewis
KD
,
Combemale
P
,
.
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
.
Lancet Oncol
.
2015 Jun
;
16
(
6
):
716
28
.
53.
Lear
JT
,
Migden
MR
,
Lewis
KD
,
Chang
ALS
,
Guminski
A
,
Gutzmer
R
,
.
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
.
J Eur Acad Dermatol Venereol
.
2018 Mar
;
32
(
3
):
372
81
.
54.
Atwood
SX
,
Sarin
KY
,
Whitson
RJ
,
Li
JR
,
Kim
G
,
Rezaee
M
,
.
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
.
Cancer Cell
.
2015 Mar
;
27
(
3
):
342
53
.
55.
Pricl
S
,
Cortelazzi
B
,
Dal Col
V
,
Marson
D
,
Laurini
E
,
Fermeglia
M
,
.
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma
.
Mol Oncol
.
2015 Feb
;
9
(
2
):
389
97
.
56.
Wang
C
,
Wu
H
,
Evron
T
,
Vardy
E
,
Han
GW
,
Huang
XP
,
.
Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs
.
Nat Commun
.
2014 Jul
;
5
:
4355
.
57.
Sharpe
HJ
,
Pau
G
,
Dijkgraaf
GJ
,
Basset-Seguin
N
,
Modrusan
Z
,
Januario
T
,
.
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma
.
Cancer Cell
.
2015 Mar
;
27
(
3
):
327
41
.
58.
Wang
C
,
Wu
H
,
Katritch
V
,
Han
GW
,
Huang
XP
,
Liu
W
,
.
Structure of the human smoothened receptor bound to an antitumour agent
.
Nature
.
2013 May
;
497
(
7449
):
338
43
.
59.
Ching
JA
,
Curtis
HL
,
Braue
JA
,
Kudchadkar
RR
,
Mendoza
TI
,
Messina
JL
,
.
The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma
.
Ann Plast Surg
.
2015 Jun
;
74
(
Suppl 4
):
S193
7
.
60.
Ally
MS
,
Ransohoff
K
,
Sarin
K
,
Atwood
SX
,
Rezaee
M
,
Bailey-Healy
I
,
.
Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma
.
JAMA Dermatol
.
2016 Apr
;
152
(
4
):
452
6
.
61.
Therasse
P
,
Arbuck
SG
,
Eisenhauer
EA
,
Wanders
J
,
Kaplan
RS
,
Rubinstein
L
,
.
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
.
J Natl Cancer Inst
.
2000 Feb
;
92
(
3
):
205
16
.
62.
Eisenhauer
EA
,
Therasse
P
,
Bogaerts
J
,
Schwartz
LH
,
Sargent
D
,
Ford
R
,
.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009 Jan
;
45
(
2
):
228
47
.
63.
Odom
D
,
Mladsi
D
,
Purser
M
,
Kaye
JA
,
Palaka
E
,
Charter
A
,
.
A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma
.
J Skin Cancer
.
2017
;
2017
:
6121760
.
64.
Calienni
MN
,
Febres-Molina
C
,
Llovera
RE
,
Zevallos-Delgado
C
,
Tuttolomondo
ME
,
Paolino
D
,
.
Nanoformulation for potential topical delivery of vismodegib in skin cancer treatment
.
Int J Pharm
.
2019 Jun
;
565
:
108
22
.
65.
Skvara
H
,
Kalthoff
F
,
Meingassner
JG
,
Wolff-Winiski
B
,
Aschauer
H
,
Kelleher
JF
,
.
Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor
.
J Invest Dermatol
.
2011 Aug
;
131
(
8
):
1735
44
.
66.
Zhao
X
,
Pak
E
,
Ornell
KJ
,
Pazyra-Murphy
MF
,
MacKenzie
EL
,
Chadwick
EJ
,
.
A transposon screen identifies loss of primary cilia as a mechanism of resistance to SMO inhibitors
.
Cancer Discov
.
2017
;
7
(
12
):
1436
49
.
67.
Whitson
RJ
,
Lee
A
,
Urman
NM
,
Mirza
A
,
Yao
CY
,
Brown
AS
,
.
Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas
.
Nat Med
.
2018
;
24
(
3
):
271
81
.
You do not currently have access to this content.